FDA Approved: PERJETA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Perjeta (pertuzumab) by Genentech, resulting in changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Perjeta (pertuzumab)

Snippet

SUPPL AP for PERJETA (PERTUZUMAB)